Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by tdon1229on Oct 25, 2021 12:35am
471 Views
Post# 34043433

RE:RE:TRIAL DATA RESULTS

RE:RE:TRIAL DATA RESULTS

Infinity wrote: Skyhawk1,  I agree you have  a good point on trial data is all that matters..  I do have a personal stake in cancer cure and a fairly substantial investment in Theralse that I believe has the potntial. 

However,  I believe the current CEO has a real job to project this trial data on a periodic basis that the previous CEO failed to do,  Shawn may very well be a knowledgable and smart CEO,  but  lacking in vision for the future.  He never  believed deep down that this therapy has exponential potential.  Shawn never had a major stake in the company that he was the CEO.  Clearly indicates that he did not believe in it being profitable.    If you  fail to  see the potential growth of the company or unable to communicate that knowlege and smarness , it is pretty much worthless. 

I would think every month or couple of weeks with an update from Roger would be great.    I believe Roger is a great communicator and I am not sure what is holding him back from issuing PR statements  that clearly outlines the progress the clinical study has made, new enrollments etc.  Basic facts on test results and future paths for this company?


Wishful thinking only sets you up for disappointment when your wishes are not realized.  

Two factors are at play here:  

1.  Theralase contracted out the trials.  The patient data and results don't belong to Theralase until the trial is complete, the data is submitted for approval, and the data is released to the company by the contractor.  The Principal Investigator determines what data gets revealed, and when, since he is responsible for the integrity of the data, as well as for coordinating with each trial site's designated principal investigator, with the company,  and with the reviewing authorities (HC and FDA).  

2.  Despite what you may think, shareholders are not entitled to know the trial data.    Many companies don't release any interim results.  The fact that the company chooses to get some data released is a bonus, but we were told we would not get information on a per patient basis for this Phase 2 trial.

As for Roger, he has been a decent entrepreneur, but I think  it's likely he lacks some of the capabilities necessary to grow the company.  Harvard Business Review identified this problem with entrepreneurs almost 50 years ago.  Simply put, the entrereneur, be he scientist, technical specialist, or engineer, who has the idea and pushes it into development most often is not the person best equipped to grow the company through its "Corridor of Crisis".  

Successful entrepreneurs bring aboard the personnel with the skills and capabilities to grow the company, even if that means stepping aside from the total leadership role.  Many entrepreneurs don't have the good sense, or the control of their egos, to relinquish their autonomous control, which explains why their entrepreneurial ventures don't thrive or become successful.





 

<< Previous
Bullboard Posts
Next >>